PT - JOURNAL ARTICLE AU - Nazarian, Alireza AU - Morado, Marissa AU - Kulminski, Alexander M. TI - Complex genetic interactions affect susceptibility to Alzheimer’s disease risk in the <em>BIN1</em> and <em>MS4A6A</em> loci AID - 10.1101/2024.10.24.24316008 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.24.24316008 4099 - http://medrxiv.org/content/early/2024/10/24/2024.10.24.24316008.short 4100 - http://medrxiv.org/content/early/2024/10/24/2024.10.24.24316008.full AB - Genetics is the second strongest risk factor for Alzheimer's disease (AD) after age. More than 70 loci have been implicated in AD susceptibility so far, and the genetic architecture of AD entails both additive and nonadditive contributions from these loci. To better understand nonadditive impact of single-nucleotide polymorphisms (SNPs) on AD risk, we examined individual, joint, and interacting (SNPxSNP) effects of 139 and 66 SNPs mapped to the BIN1 and MS4A6A AD-associated loci, respectively. The analyses were conducted by fitting three respective dominant allelic-effect models using data from four independent studies. Joint effects were analyzed by considering pairwise combinations of genotypes of the selected SNPs, i.e., compound genotypes (CompG). The individual SNP analyses showed associations of 18 BIN1 SNPs and 4 MS4A6A SNPs with AD. We identified 589 BIN1 and 217 MS4A6A SNP pairs associated with AD in the CompG analysis, although their individual SNPs were not linked to AD independently. Notably, 34 BIN1 and 10 MS4A6A SNP pairs exhibited both significant SNPxSNP interaction effects and significant CompG effects. The vast majority of nonadditive effects were captured through the CompG analysis. These results expand the current understanding of the contributions of the BIN1 and MS4A6A loci to AD susceptibility. The identified nonadditive effects suggest a significant genetic modulation mechanism underlying the genetic heterogeneity of AD in these loci. Our findings highlight the importance of considering nonadditive genetic impact on AD risk beyond the traditional SNPxSNP approximation, as they may uncover critical mechanisms not apparent when examining SNPs individually.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by Grants from the National Institute on Aging (R01AG061853, R01AG065477, and R01AG070488). The funders had no role in study design, data collection and analysis, the decision to publish, or manuscript preparation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Duke Health Institutional Review Board (IRB) gave ethical approval for this work [Pro00105245-INIT-1.0 (06/26/2020), Pro00105247-INIT-1.0 (06/26/2020), and Pro00105346-INIT-1.0 (04/15/2020)], and all analyses were performed under IRB guidelines. This study does not involve gathering data from human subjects directly. Instead, it focuses on secondary analysis of data obtained from dbGaP, NIAGADS, and the UK Biobank.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe four analyzed datasets are available to the qualified researchers by the dbGaP (ADGC, ADSP, and LOAD-FBS datasets), NIAGADS (ADSP dataset), and the UK Biobank (UKB dataset).https://www.ncbi.nlm.nih.gov/gaphttps://www.niagads.org/adsp/content/homehttps://www.ukbiobank.ac.uk